Republic Technologies Inc. Completes First Tranche of Non‑Brokered Private Placement of Special Warrants
Republic Technologies Inc. (CSE: DOCT, FSE: 7FM0, OTCQB: DOCKF) announced on March 20, 2026 that it has successfully closed the first tranche of its non‑brokered private placement of Special Warrants. The transaction followed the company’s February 13, 2026 press release and aligns with its strategy to raise capital for operational expansion and the development of its Ethereum‑powered attestation technology.
Transaction Details
| Item | Value |
|---|---|
| Number of Special Warrants issued | 9,523,808 |
| Issue price | 0.29 CAD (0.21 USD) per warrant |
| Gross proceeds | 2 million USD (≈ 2.76 million CAD) |
Each Special Warrant will automatically convert, at no additional consideration, into one common share of Republic Technologies’ capital. The conversion will occur on the earlier of:
- The date that is five business days after the company files a prospectus supplement to its short‑form base shelf prospectus with the securities commissions, qualifying the distribution of the underlying common shares; or
- The date that is four months and one day after the closing of the first tranche.
Prior to filing the prospectus supplement and conversion, the warrants are subject to a four‑month holding period in accordance with applicable law. No finder’s fees were paid in connection with the offering.
Use of Proceeds
The proceeds are earmarked for Republic Technologies’ business operations and the advancement of its core technology, particularly the Ethereum‑based attestation platform that underpins its medical technology solutions.
Market Context
- Current share price: 0.17 CAD (as of 2026‑03‑17).
- 52‑week high: 0.85 CAD (2025‑07‑02).
- 52‑week low: 0.095 CAD (2025‑03‑26).
- Market capitalization: 5,523,973 CAD.
- Price‑to‑earnings ratio: –2.172, reflecting the company’s current operating losses.
Republic Technologies has a long history of innovation in medical technology, having been incorporated in 2000 and headquartered in Vancouver, British Columbia. Its operations focus on developing and commercializing innovative medical solutions, and it trades on the Canadian National Stock Exchange as well as other Canadian and U.S. exchanges under the ticker DOCT.
The completion of the first tranche marks a significant milestone in the company’s capital‑raising efforts and supports its continued investment in technology development and market expansion.
